FDA grants accelerated approval to new treatment for advance
The U.S. Food and Drug Administration has granted accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS), which are cancers that develop in muscles, fat, tendons or other soft tissues. Lartruvo is approved for use with the FDA-approved chemotherapy drug doxorubicin for the treatment of patients with STS who cannot be cured with radiation or surgery and who have a type of STS for which an anthracycline (chemotherapy) is an appropriate treatment...


http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm525878.htm
Dr. D●●p P●●●l and 1 others like this
Like
Comment
Share